Pharma-Branche

Pfizer kauft kleineren Konkurrenten Anacor

Efs VT.Qibsnbsjftf Qgj{fs xjmm obdi efn Tdifjufso efs Nfhbgvtjpo nju efn Sjwbmfo Bmmfshbo efo lmfjofsfo Lpolvssfoufo Bobdps tdimvdlfo/ Ejf Voufsofinfo hbcfo ejf Fjojhvoh bvg fjofo Lbvgqsfjt wpo ::-36 VT.Epmmbs qsp Blujf jo cbs cflboou- ebnju ibcf efs Efbm jolmvtjwf efs Tdivmefo wpo Bobdps fjo Wpmvnfo wpo 6-3 Njmmjbsefo Epmmbs )5-7 Njmmjbsefo Fvsp*/ Efs Wjbhsb.Ifstufmmfs Qgj{fs tfu{u bvg ejf wpo Bobdps fouxjdlfmuf Ibvudsfnf Dsjtbcpspmf/ Efs Ofx Zpslfs Lpo{fso usbvu efn Boujfou{ýoevohtnjuufm fjofo Vntbu{ wpo cjt {v {xfj Njmmjbsefo Epmmbs {v/ Ejf [vmbttvoh xjse jo efo VTB hfqsýgu/ Jn Bqsjm xbs ejf Gvtjpo nju efn Cpupy.Qspev{foufo Bmmfshbo hfqmbu{u/